The UK MHRA’s comprehensive orphan drug registry delivers tangible benefits across the healthcare system. For patients, the official public registry provides transparent access to approved treatments for their rare disease condition, eliminating informational gaps that previously complicated diagnosis and treatment planning. Clinicians gain a centralised, evidence-based reference tool for rare disease pharmacotherapy, enabling more systematic and informed therapeutic decision-making.
Policymakers and NHS commissioners leverage the registry to inform funding decisions, health technology assessment processes, and resource allocation for rare disease medicines. This structured approach ensures that commissioning decisions reflect current, authoritative data on available orphan drug interventions. By consolidating information previously dispersed across multiple sources, the MHRA registry streamlines access pathways and supports equitable treatment distribution across the healthcare system, ultimately improving outcomes for patients with rare diseases across the United Kingdom.
Was this article helpful?
